Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631911 | 1.00 | REN (0.54) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1863701 | 0.95 | REN (0.54) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1863705 | 0.95 | REN (0.54) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1863699 | 0.95 | REN (0.54) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1861478 | 0.92 | REN (0.53) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1862351 | 0.92 | REN (0.53) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1861480 | 0.92 | REN (0.53) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1862352 | 0.92 | REN (0.53) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1861476 | 0.92 | REN (0.53) | RENGPR119USP30ALOX5APFEN1 | |
| SCHEMBL1865929 | 0.92 | REN (0.53) | RENGPR119USP30ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | REN 298/4885GPR119 1542/4885USP30 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.